Graves Ophthalmopathy Clinical Trials

61 clinical trials for Graves Ophthalmopathy across international registries, including 14 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Screening, Classification, and Outcome Prediction Ensemble Using Orbital MRI for Thyroid Eye Disease: The TED SCOPE National Multicenter Registry Study — RECRUITING
• Bimatoprost as a Treatment for Graves' Orbitopathy — RECRUITING · PHASE1
• Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease — RECRUITING · NA
• Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease — RECRUITING · PHASE2
• Systemic Inflammation, Thyroid Autoimmunity and Neuroretinal Changes in Graves Disease — RECRUITING
• Effect of Low-Level Light Therapy on Ocular Surface Parameters in Patients With Graves Disease — RECRUITING · NA
• Exploring Immunological Markers Associated With Mental Fatigue in Graves' Disease — RECRUITING
• Multi-center Prospective Clinical Study on Glucocorticoid Pulse Therapy for Graves' Ophthalmopathy (GO) — RECRUITING · NA
• Hydroxychloroquine in Mild Graves' Orbitopathy — RECRUITING · PHASE4
• Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) — RECRUITING · PHASE2
• Treatment of Graves´ophthalmopathy with Simvastatin (GO-S) — RECRUITING · PHASE3
• Modified Orbital Decompression in the Treatment of Moderate-to-severe Grave's Ophthalmopathy — RECRUITING · NA
• The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction — RECRUITING
• A PHASE 2A, MULTICENTER, OPEN-LABEL STUDY OF RVT-1401 FOR THE TREATMENT OF PATIENTS WITH MODERATE TO SEVERE ACTIVE GRAVES' OPHTHALMOPATHY — RECRUITING · PHASE2
• Study of Atorvastatin and Its Effects in Clinical and Radiological Aspects in Patients With Moderate-to-Severe Thyroid Eye Disease — NOT_YET_RECRUITING · PHASE1
• Prospective Observational Study of Smartphone-Based AI Self-Monitoring During Non-Surgical Treatment for Thyroid Eye Disease (THYROSCOPE) — NOT_YET_RECRUITING
• Teprotumumab N01 Versus Methylprednisolone After Urgent Orbital Decompression for Dysthyroid Optic Neuropathy — NOT_YET_RECRUITING · PHASE2
• A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease — COMPLETED · PHASE2
• Glucocorticoids and Bone in Graves' Ophthalmopathy — COMPLETED
• A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) — ACTIVE_NOT_RECRUITING · PHASE2
• Treatment of Graves´ ophthalmopathy with diclofenak or simvastatin — TERMINATED · PHASE3
• A Randomized Clinical Trial of Intravenous Methylprednisolone With 2 Protocols in Patients With Graves Orbitopathy — NOT_YET_RECRUITING · PHASE4
• Study on Efficacy of Add on Selenium in Mild-to-moderate Graves Ophthalmopathy — OTHER · NA
• Therapeutic Efficacy of Orbital Radiotherapy in Patients With Graves' Orbitopathy — COMPLETED
• Comparison of the Effectiveness of Two Glucocorticoid Regimens for Treatment of Graves' Orbitopathy — COMPLETED
• Sirolimus for Graves' Orbitopathy (GO) — OTHER · PHASE2
• ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO ) — TERMINATED · PHASE2
• Rapamycin Plus Methylprednisolone Versus Methylprednisolone Alone in Active, Moderate-to-severe Graves' Orbitopathy. — OTHER · PHASE1
• Tocilizumab in Active Moderate-severe Graves' Orbitopathy — OTHER · PHASE2
• Sirolimus in Graves' Orbitopathy — COMPLETED
• Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO) — COMPLETED · PHASE2
• Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy — OTHER · PHASE2
• Supramaximal Rectus Recession for Strabismus in Grave's Ophthalmopathy — OTHER · NA
• Exophthalmometry With 3D Face Scanners — OTHER · NA
• A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease — TERMINATED · PHASE2
• Genetics and Epigenetics of Graves' Orbitopathy — COMPLETED
• Heart Rhythm After Intravenous Methylprednisolone Administration — COMPLETED
• Analysis Between the Results of Two Surgical Techniques of Orbital Decompression in Patients With Graves Orbitopathy — COMPLETED · NA
• Liver Function After Intravenous Methylprednisolone Administration — COMPLETED · PHASE4
• Anti-insulin-like Growth Factor-1 Receptor (IGF-1R) Antibodies in Graves' Disease and Graves' Orbitopathy — COMPLETED
• Impact of Intravenous Methylprednisolone Treatment on Blood Pressure — COMPLETED
• Coagulation After Intravenous Methylprednisolone Administration — COMPLETED
• T and B Cells in Graves' Orbitopathy — COMPLETED
• Retinal Oxygen Saturation in Patients With Graves' Ophthalmopathy and in Normal People — OTHER
• Observing the Relationship of Fibroblast Growth Factor and Fibroblast in Thyroid Eye Disease — OTHER
• Graves' Orbitopathy and Hypercholesterolemia — COMPLETED
• Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy — WITHDRAWN · PHASE1
• Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy — OTHER · PHASE3
• Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study) — COMPLETED · PHASE4
• Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease) — COMPLETED · PHASE3

Refine this search